FDA recalling select desmopressin nasal spray products
On August 5, 2020, the U.S. Food and Drug Administration (FDA) requested that prescription desmopressin nasal spray products including brands Stimate® and DDAVP®, manufactured by Ferring Pharmaceuticals, be removed from the market due to superpotency.
Desmopressin nasal spray products are used to treat symptoms of central diabetes insipidus, von Willebrand’s disease, and hemophilia A.
We're notifying members
We’re sending letters to impacted members, asking that they contact their pharmacy about getting a replacement product. Dispensing pharmacies are also required to contact them if they’ve received a recalled product.
What do you need to do?
Dispensing pharmacies are contacting any patients who have received a recalled product and are automatically replacing orders for the recalled product with a safe alternative.
Prescribing providers do not need to take any action to ensure their patients can receive a replacement product. However, members may reach out to their provider to see if a different treatment option may be appropriate, due to the unique disease states this product is used for.